533 research outputs found
Data on isoaspartylation of neuronal ELAVL proteins
No full textAbstractThis article contains experimental data examining the propensity of neuronal ELAVL proteins to become isoaspartylated. The data are related to the article “Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4” (M.A. Pulido, M.K. DerHartunian, Z. Qin, E.M. Chung, D.S. Kang, A.W. Woodham, J.A. Tsou, R. Klooster, O. Akbari, L. Wang, W.M. Kast, S.V. Liu, J.J.G.M. Verschuuren, D.W. Aswad, I.A. Laird-Offringa, 2016) [1], in which it was reported that the N-terminal region of recombinant human ELAVL4 protein, incubated under physiological conditions, acquires a type of highly immunogenic protein damage. Here, we present Western blot analysis data generated by using an affinity-purified polyclonal rabbit antibody (raised against an N-terminal ELAVL4 isoaspartyl-converted peptide) to probe recombinant protein fragments of the other three members of the ELAVL family: the highly homologous neuronal ELAVL2 (HuB) and ELAVL3 (HuC), and the much less homologous ubiquitously expressed ELAVL1 (HuR)
, Ross Laird
No full textRoss Laird, PhD RCC is a clinical consultant focused on trauma, addictions, and social vulnerability. He is also a best-selling author, award-winning scholar and educator, and clinical supervisor for BC’s largest licensed non-profit program in addictions, trauma, and mental health. Dr. Laird focuses particularly on traumatized and marginalized client populations — those navigating homelessness, mental illness, and complex trauma — and provides professional development training for organizations that serve them: social service agencies, first responders, cultural groups, nonprofits, and educational institutions. He also works extensively with organizations in arts and culture and Indigenous communities to develop trauma-informed practices for cultural programming, museum exhibitions, and community initiatives
Tumbled smooth by the rapids: Rediscovering and reconnecting in the wake of turbulence
No full textRoss Laird, PhD RCC is a clinical consultant focused on trauma, addictions, and social vulnerability. He is also a best-selling author, award-winning scholar and educator, and clinical supervisor for BC’s largest licensed non-profit program in addictions, trauma, and mental health. Dr. Laird focuses particularly on traumatized and marginalized client populations — those navigating homelessness, mental illness, and complex trauma — and provides professional development training for organizations that serve them: social service agencies, first responders, cultural groups, nonprofits, and educational institutions. He also works extensively with organizations in arts and culture and Indigenous communities to develop trauma-informed practices for cultural programming, museum exhibitions, and community initiatives.presentationBetter Together Conferenc
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
No full textAbstract Small-cell lung cancer (SCLC) is the most aggressive lung cancer subtype and lacks effective early detection methods and therapies. A number of rare paraneoplastic neurologic autoimmune diseases are strongly associated with SCLC. Most patients with such paraneoplastic syndromes harbor high titers of antibodies against neuronal proteins that are abnormally expressed in SCLC tumors. These autoantibodies may cross-react with the nervous system, possibly contributing to autoimmune disease development. Importantly, similar antibodies are present in many SCLC patients without autoimmune disease, albeit at lower titers. The timing of autoantibody development relative to cancer and the nature of the immune trigger remain to be elucidated. Here we review what is currently known about SCLC-associated autoantibodies, and describe a recently developed mouse model system of SCLC that appears to lend itself well to the study of the SCLC-associated immune response. We also discuss potential clinical applications for these autoantibodies, such as SCLC diagnosis, early detection, and therapy.</p
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy
No full text- …
